ArticleEuropean journal of breast health2022

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction.

İrfan Cicin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.